Beacon Investment Advisory Services Inc. Sells 860 Shares of Eli Lilly and Company $LLY

Beacon Investment Advisory Services Inc. lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 4.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 17,158 shares of the company’s stock after selling 860 shares during the period. Beacon Investment Advisory Services Inc.’s holdings in Eli Lilly and Company were worth $20,580,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Quantum Financial Advisors LLC grew its stake in Eli Lilly and Company by 2.3% in the second quarter. Quantum Financial Advisors LLC now owns 1,589 shares of the company’s stock valued at $1,906,000 after purchasing an additional 36 shares in the last quarter. Williams & Novak LLC bought a new stake in shares of Eli Lilly and Company during the 2nd quarter worth approximately $507,000. Trust Point Inc. boosted its holdings in shares of Eli Lilly and Company by 9.7% in the 2nd quarter. Trust Point Inc. now owns 2,996 shares of the company’s stock valued at $3,593,000 after buying an additional 264 shares during the last quarter. Strategic Investment Solutions Inc. IL grew its stake in shares of Eli Lilly and Company by 24.7% in the second quarter. Strategic Investment Solutions Inc. IL now owns 929 shares of the company’s stock valued at $1,115,000 after buying an additional 184 shares in the last quarter. Finally, First Heartland Consultants Inc. grew its stake in shares of Eli Lilly and Company by 6.5% in the second quarter. First Heartland Consultants Inc. now owns 4,010 shares of the company’s stock valued at $4,809,000 after buying an additional 245 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 0.4%

Shares of LLY opened at $1,186.71 on Friday. The firm has a market cap of $1.12 trillion, a P/E ratio of 39.82, a price-to-earnings-growth ratio of 1.38 and a beta of 0.51. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.10 and a current ratio of 1.35. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,249.45. The firm’s 50-day simple moving average is $1,159.38 and its 200 day simple moving average is $1,047.55.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period last year, the business posted $6.31 earnings per share. The business’s revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts forecast that Eli Lilly and Company will post 37.55 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 23.22%.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Rothschild & Co Redburn increased their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. BMO Capital Markets reiterated an “outperform” rating and issued a $1,400.00 target price on shares of Eli Lilly and Company in a research note on Thursday. Leerink Partners lifted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Finally, Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,292.18.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Beat-and-raise quarter reinforces growth outlook. Lilly reported second-quarter revenue of approximately $22.97 billion and EPS of $8.38, exceeding consensus estimates. Revenue increased 47.7% year over year, and management raised 2026 revenue guidance to $85 billion-$87 billion from $82 billion-$85 billion, primarily because of strong demand for its diabetes and obesity medicines. Eli Lilly raises 2026 outlook again as Q2 soars past estimates
• Positive Sentiment: Weight-loss portfolio continues to drive investor enthusiasm. Mounjaro sales rose 91%, while Mounjaro and Zepbound together generated nearly $15 billion, widening Lilly’s lead over Novo Nordisk. Foundayo adoption is also gaining traction, Medicare access is expanding, and retatrutide is progressing toward a potential 2027 regulatory filing. LLY Q2 Earnings Call Raises Outlook as Foundayo Gains Traction
• Positive Sentiment: Analysts remain bullish. Truist raised its price target to $1,376 and maintained a Buy rating, while Cantor Fitzgerald lifted its target to $1,410 with an Overweight rating. Analysts cited durable incretin demand and the stronger long-term growth outlook. Eli Lilly’s Incretin Performance Supports Long-Term Growth
• Positive Sentiment: Favorable legal news removes a potential overhang. Lilly and Novo Nordisk defeated an antitrust lawsuit concerning the GLP-1 drug market, reducing near-term litigation risk. Lilly, Novo defeat antitrust lawsuit over GLP-1 drug market
• Neutral Sentiment: Retatrutide is being offered to some patients before FDA approval. Early access could generate real-world experience and strengthen demand, but the treatment remains subject to regulatory approval and related safety scrutiny. Eli Lilly offers new weight loss drug to some patients before FDA approval
• Negative Sentiment: Profit-taking and valuation concerns may be limiting the response. Following the earnings-driven advance, Lilly trades at roughly 40 times earnings and near its record high. Investors may be demanding continued execution, while expanding access through Amazon and competing obesity drugs could increase pricing and market-share pressure.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.